alanine has been researched along with raltegravir potassium in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jones, R; Levy, JB; Milburn, J | 1 |
Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G | 1 |
1 review(s) available for alanine and raltegravir potassium
Article | Year |
---|---|
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
1 other study(ies) available for alanine and raltegravir potassium
Article | Year |
---|---|
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome | 2018 |